Novo Nordisk completes acquisition of Emisphere Technologies

Novo Nordisk has completed the acquisition of Emisphere Technologies, by which it secures the full rights to the technology which has made the diabetes tablet Rybelsus possible, which the firm also plans to use in other treatments.

Photo: Tidsvilde Stine/Ritzau Scanpix

On Tuesday, Novo Nordisk completed the acquisition of Emisphere Technologies, according to a statement from the pharmaceutical giant.

"The adoption of the merger agreement was approved by Emisphere shareholders today," writes Novo Nordisk in the announcement. In November, the US authorities granted the firm an early termination of the waiting period.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs